SPV-30 boxwood evergreen tree extract slows HIV/AIDS progress in two studies.
This article was originally published in The Tan Sheet
Executive Summary
BOXWOOD EVERGREEN TREE EXTRACT SLOWS HIV/AIDS PROGRESS IN TWO STUDIES presented at the XI International Conference on AIDS in Vancouver, one a clinical trial conducted in France, and the other an "informal" six-month study enrolling 400 subjects in the U.S. The proprietary standardized extract is marketed in France by Arkopharma under the product name SPV-30 and distributed in the U.S. by the Health Connection, based in Jericho, N.Y.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning